For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  Inclusion Criteria:  Histologically confirmed advanced or recurrent NSCLC  Participants who have received or scheduled to administrate nivolumab plus ipilimumab with or without chemotherapy as first-line treatment from the date of approval of nivolumab plus ipilimumab with or without chemotherapy to November 30, 2021.  Pemetrexed plus cisplatin or carboplatin for participants with non- squamous histology and paclitaxel plus carboplatin for participants with squamous histology are only acceptable combinations of chemotherapy.  Exclusion Criteria:  In participants with non-squamous histology, participants who are confirmed to be positive for EGFR gene mutation or ALK fusion gene for which EGFR tyrosine kinase inhibitor or ALK tyrosine kinase inhibitor is indicated. Participants who had antineoplastic treatment as first-line treatment of advanced or recurrent NSCLC prior to initiation of nivolumab plus ipilimumab with or without chemotherapy.  However, participants who correspond to a) or b) below will be included in this study.  Prior perioperative chemotherapy or Stage III chemoradiotherapy or durvalumab combination chemoradiotherapy.  Participants who are received or have received bisphosphonates or denosumab for bone metastasis  Participants who initiated treatment with nivolumab plus ipilimumab and added chemotherapy from the second course onwards. Participants who received investigational anti-tumor drug in clinical trial after being diagnosed with NSCLC Other participants who are judged by the investigators to be inappropriate for enrollment in this study  Other protocol-defined inclusion/exclusion criteria apply